BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Norinchukin Bank, The | 5,373 | $365,740 | 0.01% |
| TORONTO DOMINION BANK | 81,453 | $5,544,506 | 0.01% |
| GUGGENHEIM CAPITAL LLC | 15,780 | $1,074,144 | 0.01% |
| Vestcor Inc | 3,684 | $251 | 0.01% |
| PNC FINANCIAL SERVICES GROUP, INC. | 133,260 | $9,070,990 | 0.01% |
| ROYAL BANK OF CANADA | 411,461 | $28,008,000 | 0.01% |
| Envestnet Portfolio Solutions, Inc. | 25,435 | $1,731,353 | 0.01% |
| IFP Advisors, Inc | 2,488 | $169,417 | 0.01% |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 16,847 | $1,146,775 | 0.01% |
| BROWN ADVISORY INC | 67,775 | $4,613,465 | 0.01% |
| GREAT WEST LIFE ASSURANCE CO /CAN/ | 50,448 | $3,434 | 0.01% |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 24,876 | $1,693,309 | 0.01% |
| BANCO BILBAO VIZCAYA ARGENTARIA, S.A. | 8,699 | $594,607 | 0.01% |
| GOLDMAN SACHS GROUP INC | 552,961 | $37,640,067 | 0.01% |
| FMR LLC | 1,329,886 | $90,525,370 | 0.01% |
| COLDSTREAM CAPITAL MANAGEMENT INC | 3,759 | $255,902 | 0.01% |
| Banque Cantonale Vaudoise | 2,000 | $136 | 0.01% |
| Rafferty Asset Management, LLC | 16,426 | $1,118,118 | 0.01% |
| Daiwa Securities Group Inc. | 13,500 | $919 | 0.01% |
| PANAGORA ASSET MANAGEMENT INC | 15,913 | $1,083,198 | 0.01% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.